Skip to main content

Summary

for males ages 18 years and up (full criteria)
at San Francisco, California
study started
estimated completion:

Description

Summary

The investigators are imaging patients with prostate cancer using a new PET imaging agent (Ga-68-PSMA-11) in order to evaluate it's ability to detection prostate cancer in patients with biochemical recurrence after prostatectomy and radiation therapy.

Keywords

Prostate Cancer Recurrence

Eligibility

You can join if…

Open to males ages 18 years and up

  • Histopathologically proven prostate adenocarcinoma.
  • Rising PSA (at least two consecutive rising PSAs) after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy).
  • Post radical prostatectomy (RP) - AUA recommendation for biochemical recurrence after radical prostatectomy
  • PSA greater than or equal to 0.2 ng/mL measured more than 6 weeks after RP.
  • Post-radiation therapy -ASTRO-Phoenix consensus definition of biochemical recurrence after radiation therapy
  • Nadir + greater than or equal to 2 ng/mL rise in PSA
  • Karnofsky performance status of > 50 (or ECOG/WHO equivalent).
  • Age > 18.
  • Ability to understand a written informed consent document, and the willingness to sign it.

You CAN'T join if...

  • Unable to lie flat, still or tolerate a PET scan.
  • Concomitant investigational therapy.
  • Patient undergoing active treatment for non-prostate malignancy, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and superficial bladder cancer.
  • Contraindication to furosemide administration including prior allergy or adverse reaction to furosemide or sulfa drugs. (Note: This exclusion criteria can be removed if Furosemide is omitted as part of the PET imaging protocol if a second-generation scatter correction is available for the used PET device).

Location

  • UCSF Imaging Center at China Basin accepting new patients
    San Francisco, California, 94107, United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT03353740
Phase
Phase 3
Lead Scientist
Thomas Hope
Study Type
Interventional
Last Updated
November 21, 2017
I’m interested in this study!